Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 10, 2022

Comparative Effectiveness and Safety Among Apixaban, Dabigatran, Edoxaban, and Rivaroxaban for Atrial Fibrillation

Annals of Internal Medicine


Additional Info

Annals of Internal Medicine
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
Ann. Intern. Med 2022 Nov 01;[EPub Ahead of Print], WCY Lau, CO Torre, KKC Man, HM Stewart, S Seager, M Van Zandt, C Reich, J Li, J Brewster, GYH Lip, AD Hingorani, L Wei, ICK Wong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading